Atea Pharmaceuticals (AVIR) Amortizatization of Intangibles (2022 - 2026)
Atea Pharmaceuticals (AVIR) recorded quarterly Amortizatization of Intangibles of $581000.0 in Q1 2026, down 28.09% quarter-over-quarter from $808000.0 in Q4 2025, and down 66.61% on a YoY basis from $1.7 million in Q1 2025.
Atea Pharmaceuticals (AVIR) Amortizatization of Intangibles (2022 - 2026) Analysis & Trends
Atea Pharmaceuticals' Amortizatization of Intangibles history runs 5 years deep, the most recent figure standing at $581000.0 for Q1 2026.
- In Q1 2026, Amortizatization of Intangibles fell 66.61% year-over-year to $581000.0; the TTM figure through Mar 2026 stood at $3.8 million (down 62.42% YoY), while the FY2025 annual figure was $4.9 million, down 58.18% from the prior year.
- Amortizatization of Intangibles was $581000.0 for Q1 2026 at Atea Pharmaceuticals, down from $808000.0 in the prior quarter.
- In the past five years, Amortizatization of Intangibles ranged from a high of $7.9 million in Q4 2022 to a low of $581000.0 in Q1 2026.
- Historically, Amortizatization of Intangibles has averaged $2.9 million across 5 years, with a median of $2.9 million in 2024.
- The sharpest annual moves came in 2024 and 2025: Amortizatization of Intangibles increased 12.99% in 2024, then sank 70.22% in 2025.
- A 5-year view of Amortizatization of Intangibles shows it stood at $7.9 million in 2022, then tumbled by 45.21% to $4.3 million in 2023, then plunged by 37.56% to $2.7 million in 2024, then tumbled by 70.22% to $808000.0 in 2025, then declined by 28.09% to $581000.0 in 2026.
- The last three Amortizatization of Intangibles figures came in at $581000.0 (Q1 2026), $808000.0 (Q4 2025), and $1.1 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | 13,267.00 |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | - |
| 10 | Atea Pharmaceuticals | 347.28 Mn | 347.28 Mn | - | 581,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 581,000.00 |
| Mar 31, 2026 | 581,000.00 |
| Dec 31, 2025 | 808,000.00 |
| Dec 31, 2025 | 808,000.00 |
| Sep 30, 2025 | 1.08 Mn |
| Sep 30, 2025 | 1.08 Mn |
| Jun 30, 2025 | 1.32 Mn |
| Jun 30, 2025 | 1.32 Mn |
| Mar 31, 2025 | 1.74 Mn |
| Mar 31, 2025 | 1.74 Mn |
| Dec 31, 2024 | 2.71 Mn |
| Dec 31, 2024 | 2.71 Mn |
| Sep 30, 2024 | 2.60 Mn |
| Sep 30, 2024 | 2.60 Mn |
| Jun 30, 2024 | 3.02 Mn |
| Jun 30, 2024 | 3.02 Mn |
| Mar 31, 2024 | 3.49 Mn |
| Mar 31, 2024 | 3.49 Mn |
| Dec 31, 2023 | 4.35 Mn |
| Dec 31, 2023 | 4.35 Mn |